Galmed unveils LNP cardiac-targeted Aramchol formulation with Barcode Nanotech
The companies developed a lipid nanoparticle version of Aramchol designed to reach heart tissue instead of the liver, according to a July 16, 2026 filing.
SEC filing
Latest
1 story